^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P18: Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer
Published date:
01/28/2022
Excerpt:
Overall, 3 partial responses were observed (2 with KRAS G12D, 1 with KRAS G12R); the objective response rate was 16.7% (95% CI 4.0-41.4). At 8 weeks, the disease control rate was 66.7% (95% CI 41.0-86.7)….Combination treatment of regorafenib and oral methotrexate in patients with KRAS mutant NSCLC was limited due to toxicity.
Secondary therapy:
methotrexate
Trial ID:
